652 related articles for article (PubMed ID: 24837362)
1. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
[TBL] [Abstract][Full Text] [Related]
2. Tissue-selective estrogen complexes for postmenopausal women.
Mirkin S; Komm BS
Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
[TBL] [Abstract][Full Text] [Related]
3. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
Bachmann G; Bobula J; Mirkin S
Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens.
Bushmakin AG; Abraham L; Pinkerton JV; Cappelleri JC; Mirkin S
Menopause; 2014 Aug; 21(8):815-22. PubMed ID: 24378765
[TBL] [Abstract][Full Text] [Related]
6. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
Pinkerton JV; Pickar JH; Racketa J; Mirkin S
Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
[TBL] [Abstract][Full Text] [Related]
7. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.
Abraham L; Bushmakin AG; Dragon E; Komm BS; Pinkerton JV
Maturitas; 2016 Dec; 94():173-179. PubMed ID: 27823739
[TBL] [Abstract][Full Text] [Related]
8. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
Komm BS; Mirkin S; Jenkins SN
Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
[TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms.
Mirkin S; Ryan KA; Chandran AB; Komm BS
Maturitas; 2014 Jan; 77(1):24-31. PubMed ID: 24246155
[TBL] [Abstract][Full Text] [Related]
10. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
[TBL] [Abstract][Full Text] [Related]
11. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH
Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382
[TBL] [Abstract][Full Text] [Related]
12. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.
Pinkerton JV; Bushmakin AG; Komm BS; Abraham L
Maturitas; 2017 Jun; 100():57-63. PubMed ID: 28539177
[TBL] [Abstract][Full Text] [Related]
13. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial.
Pinkerton JV; Pan K; Abraham L; Racketa J; Ryan KA; Chines AA; Mirkin S
Menopause; 2014 Mar; 21(3):252-9. PubMed ID: 23942245
[TBL] [Abstract][Full Text] [Related]
14. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
Palacios S; Currie H; Mikkola TS; Dragon E
Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
[TBL] [Abstract][Full Text] [Related]
15. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
Pickar JH; Mirkin S
Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
[TBL] [Abstract][Full Text] [Related]
16. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis.
Hadji P; Ryan KA; Yu CR; Mirkin S; Komm BS
Climacteric; 2016 Oct; 19(5):482-7. PubMed ID: 27631562
[TBL] [Abstract][Full Text] [Related]
17. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.
Pinkerton JV; Komm BS; Mirkin S
Climacteric; 2013 Dec; 16(6):618-28. PubMed ID: 23805785
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population.
Palacios S; Arias L; Lavenberg J; Pan K; Mirkin S; Komm BS
Climacteric; 2016 Jun; 19(3):261-7. PubMed ID: 26940720
[TBL] [Abstract][Full Text] [Related]
19. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling.
Pinkerton JV; Bushmakin AG; Racketa J; Cappelleri JC; Chines AA; Mirkin S
Menopause; 2014 Mar; 21(3):243-51. PubMed ID: 23899830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
